The Impact of the COVID-19 Lockdown on the Quality of Life in Chronic Neurological Diseases: The Results of a COVQoL-CND Study.


Journal

European neurology
ISSN: 1421-9913
Titre abrégé: Eur Neurol
Pays: Switzerland
ID NLM: 0150760

Informations de publication

Date de publication:
2021
Historique:
received: 24 03 2021
accepted: 22 05 2021
pubmed: 4 8 2021
medline: 26 11 2021
entrez: 3 8 2021
Statut: ppublish

Résumé

Coronavirus disease 2019 (COVID-19) pandemic and lockdown period may induce an impairment in quality of life (QoL), disruption in treatment (DIT), and posttraumatic stress disorder (PTSD) in chronic neurological diseases (CNDs). To reach this information, a multicenter, cross-sectional study (COVQoL-CND) was planned. Parkinson's disease (PD), headache (HA), multiple sclerosis (MS), epilepsy (EP), polyneuropathy (PNP), and cerebrovascular disease (CVD) were selected as the CND. The COVQoL-CND study includes demographic data, the World Health Organization Quality of Life short form (WHOQOL-BREF), and Impact of Event Scale-Revised (IES-R) forms. The mean age of a total of 577 patients was 49 ± 17 (19-87 years), and the ratio of female/male was 352/225. The mean age of patients with PD, HA, MS, EP, PNP, and CVD were 65 ± 11, 39 ± 12, 38 ± 10, 47 ± 17, 61 ± 12, and 60 ± 15 years, respectively. The IES-R scores were found to be higher in the younger group, those with comorbid disease, contacted with CO-VID-19 patients, or diagnosed with COVID-19. In the group with a high IES-R score, the rate of DIT was found to be high. IES-R scores were negatively correlated with QoL. IES-R total scores were found highest in the CVD group and lowest in the PD group. The ratio of DIT was found highest in the PNP group and the lowest in the EP group. Contact with CO-VID-19 patients was high in the EP and HA group. The results of the COVQoL-CND study showed that lockdown causes posttraumatic stress and deterioration in the QoL in CND.

Sections du résumé

BACKGROUND
Coronavirus disease 2019 (COVID-19) pandemic and lockdown period may induce an impairment in quality of life (QoL), disruption in treatment (DIT), and posttraumatic stress disorder (PTSD) in chronic neurological diseases (CNDs). To reach this information, a multicenter, cross-sectional study (COVQoL-CND) was planned. Parkinson's disease (PD), headache (HA), multiple sclerosis (MS), epilepsy (EP), polyneuropathy (PNP), and cerebrovascular disease (CVD) were selected as the CND.
METHODS
The COVQoL-CND study includes demographic data, the World Health Organization Quality of Life short form (WHOQOL-BREF), and Impact of Event Scale-Revised (IES-R) forms.
RESULTS
The mean age of a total of 577 patients was 49 ± 17 (19-87 years), and the ratio of female/male was 352/225. The mean age of patients with PD, HA, MS, EP, PNP, and CVD were 65 ± 11, 39 ± 12, 38 ± 10, 47 ± 17, 61 ± 12, and 60 ± 15 years, respectively. The IES-R scores were found to be higher in the younger group, those with comorbid disease, contacted with CO-VID-19 patients, or diagnosed with COVID-19. In the group with a high IES-R score, the rate of DIT was found to be high. IES-R scores were negatively correlated with QoL. IES-R total scores were found highest in the CVD group and lowest in the PD group. The ratio of DIT was found highest in the PNP group and the lowest in the EP group. Contact with CO-VID-19 patients was high in the EP and HA group.
CONCLUSIONS
The results of the COVQoL-CND study showed that lockdown causes posttraumatic stress and deterioration in the QoL in CND.

Identifiants

pubmed: 34344010
pii: 000517380
doi: 10.1159/000517380
pmc: PMC8450832
doi:

Types de publication

Journal Article Multicenter Study

Langues

eng

Sous-ensembles de citation

IM

Pagination

450-459

Informations de copyright

© 2021 S. Karger AG, Basel.

Auteurs

Sevki Sahin (S)

Department of Neurology, Maltepe University, School of Medicine, Istanbul, Turkey.

Sibel Karsidag (S)

Department of Neurology, Maltepe University, School of Medicine, Istanbul, Turkey.

Nilgun Cinar (N)

Department of Neurology, Maltepe University, School of Medicine, Istanbul, Turkey.

Miruna Florentina Ates (MF)

Department of Neurology, Maltepe University, School of Medicine, Istanbul, Turkey.

Serkan Demir (S)

Department of Neurology, University of Health Sciences, Sancaktepe Research and Training Hospital, Istanbul, Turkey.

Fettah Eren (F)

Department of Neurology, Selcuk University, School of Medicine, Konya, Turkey.

Abdurrahman Neyal (A)

Dr. Ersin Arslan Research and Training Hospital, Gaziantep, Turkey.

Aysin Kisabay Ak (A)

Department of Neurology, Celal Bayar University School of Medicine, Manisa, Turkey.

Ayse Bora Tokcaer (A)

Department of Neurology, Gazi University, School of Medicine, Ankara, Turkey.

Esra Erkoc Ataoglu (E)

Department of Neurology, Gazi University, School of Medicine, Ankara, Turkey.

Seda Nur Akkaya (SN)

Department of Neurology, Gazi University, School of Medicine, Ankara, Turkey.

Esra Aciman Demirel (E)

Department of Neurology, Bülent Ecevit University Faculty of Medicine, Zonguldak, Turkey.

Filiz Koc (F)

Department of Neurology, Cukurova University, Faculty of Medicine, Adana, Turkey.

Serefnur Ozturk (S)

Department of Neurology, Selcuk University, School of Medicine, Konya, Turkey.

Yasemin Ekmekyapar Firat (Y)

Department of Neurology, SANKO University, School of Medicine, Gaziantep, Turkey.

Tugba Okluoglu (T)

Department of Neurology, Health Sciences University, Istanbul Education Research Hospital, Istanbul, Turkey.

Erdem Togrol (E)

Department of Neurology, University of Health Science, Hamidiye School of Medicine, Sultan Abdulhamid Han Research and Training Hospital, Istanbul, Turkey.

Ali Kemal Erdemoglu (AK)

Erdemoglu Neurology and Pain Clinic, Ankara, Turkey.

Nesrin Ergin (N)

Department of Neurology, Pamukkale University, Medical Faculty, Denizli, Turkey.

Refah Sayin (R)

Department of Neurology, Ufuk University, School of Medicine, Ankara, Turkey.

Aysegul Demir (A)

Department of Neurology, Konya City Hospital, Konya, Turkey.

Sueda Ecem Yilmaz (SE)

Department of Neurology, Selcuk University, School of Medicine, Konya, Turkey.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH